Nymox Pharmaceutical (Nymox Pharmaceutical) EV-to-EBIT

: -16.43 (As of Today)

View and export this data going back to 1997. Start your Free Trial

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Nymox Pharmaceutical's Enterprise Value is $27.92 Mil. Nymox Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $-1.70 Mil. Therefore, Nymox Pharmaceutical's EV-to-EBIT for today is -16.43.

The historical rank and industry rank for Nymox Pharmaceutical's EV-to-EBIT or its related term are showing as below:

NYMXF' s EV-to-EBIT Range Over the Past 10 Years
Min: -172.65 Med: -11.33 Max: -1.23
Current: -16.43

During the past 13 years, the highest EV-to-EBIT of Nymox Pharmaceutical was -1.23. The lowest was -172.65. And the median was -11.33.

NYMXF's EV-to-EBIT is ranked worse than
100% of 444 companies
in the Biotechnology industry
Industry Median: 8.185 vs NYMXF: -16.43

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Nymox Pharmaceutical's Enterprise Value for the quarter that ended in Sep. 2023 was $48.90 Mil. Nymox Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $-1.70 Mil. Nymox Pharmaceutical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -3.47%.

Nymox Pharmaceutical EV-to-EBIT Historical Data

The historical data trend for Nymox Pharmaceutical's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nymox Pharmaceutical Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EV-to-EBIT

Get a 7-Day Free Trial

-7.26

-11.55

-16.26

-8.86

-4.29

Nymox Pharmaceutical Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EV-to-EBIT	Get a 7-Day Free Trial															-3.18	-4.29	-10.75	-8.32	-28.78

Competitive Comparison

For the Biotechnology subindustry, Nymox Pharmaceutical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nymox Pharmaceutical EV-to-EBIT Distribution

For the Biotechnology industry and Healthcare sector, Nymox Pharmaceutical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Nymox Pharmaceutical's EV-to-EBIT falls into.

Nymox Pharmaceutical EV-to-EBIT Calculation

Nymox Pharmaceutical's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	27.915	/	-1.699
	=	-16.43

Nymox Pharmaceutical's current Enterprise Value is $27.92 Mil.
Nymox Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.70 Mil.

Nymox Pharmaceutical (OTCPK:NYMXF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Nymox Pharmaceutical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2023 )	=	EBIT	/	Enterprise Value (Q: Sep. 2023 )
	=	-1.699	/	48.899125
	=	-3.47 %

Nymox Pharmaceutical's Enterprise Value for the quarter that ended in Sep. 2023 was $48.90 Mil.
Nymox Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.70 Mil.

Nymox Pharmaceutical EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Nymox Pharmaceutical's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Nymox Pharmaceutical (Nymox Pharmaceutical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nymox Pharmaceutical Corp (OTCPK:NYMXF) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

Bay & Deveaux Streets, Nassau, BHS

Website

https://www.nymox.com

Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and the treatment of low-grade localized prostate cancer. It markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. It operates in a single segment, which is research and development of products for the aging population. The company's geographical segments include Canada, United States, and Europe.

Executives

James George Robinson	director	10 EAST LEE STREET, SUITE 2705, BALTIMORE MD 21202
Erik Danielsen	officer: Chief Financial Officer	9900 CAVENDISH BLVD, ST LAURENT A8 H4M 2V2
Paul Averback	director, 10 percent owner, officer: CEO	C/O NYMOX PHARMACEUTICAL CORPORATION, 9900 CAVENDISH BLVD., SUITE 306, ST. LAURENT A8 H4M 2V2
Randall J Lanham	director, officer: General Counsel